Literature DB >> 27646695

Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study.

K H Mikkelsen1,2, F K Knop1,3, T Vilsbøll1, M Frost4, J Hallas5, A Pottegård5.   

Abstract

AIMS: To investigate whether the use of antibiotics from infancy to adolescence influences the risk of Type 1 diabetes.
METHODS: We conducted a population-based case-control study, including all Type 1 diabetes cases in Denmark among children born between 1997 and 2012 (n = 1578). Odds ratios associating Type 1 diabetes with use of antibiotics were calculated using conditional logistic regression.
RESULTS: Overall, we found no association between the use of antibiotics and risk of Type 1 diabetes. Furthermore, no associations were seen specifically for broad-spectrum, narrow-spectrum, bactericidal or bacteriostatic types of antibiotics or for the most frequently used individual classes of antibiotics. No differences were observed in subgroups defined by sex or by age at time of diagnosis. However, filling five or more antibiotic prescriptions in the first 2 years of life specifically was associated with a higher odds ratio of 1.35 (95% CI 1.10-1.64). This association appeared to be driven by exposure to broad-spectrum antibiotics within the second year of life.
CONCLUSION: Antibiotic exposure in childhood is generally not associated with the risk of developing Type 1 diabetes. Future studies should investigate the effects of multiple exposures to broad-spectrum antibiotics during the second year of life.
© 2016 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27646695     DOI: 10.1111/dme.13262

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  18 in total

Review 1.  Early life origin of type 1 diabetes.

Authors:  Mikael Knip; Kristiina Luopajärvi; Taina Härkönen
Journal:  Semin Immunopathol       Date:  2017-11-23       Impact factor: 9.623

2.  Does the Receipt of Antibiotics for Common Infectious Diseases Predispose to Kidney Stones? A Cautionary Note for All Health Care Practitioners.

Authors:  Lama Nazzal; Martin J Blaser
Journal:  J Am Soc Nephrol       Date:  2018-05-10       Impact factor: 10.121

Review 3.  Type 1 diabetes-early life origins and changing epidemiology.

Authors:  Jill M Norris; Randi K Johnson; Lars C Stene
Journal:  Lancet Diabetes Endocrinol       Date:  2020-01-27       Impact factor: 32.069

Review 4.  The hygiene hypothesis in autoimmunity: the role of pathogens and commensals.

Authors:  Jean-François Bach
Journal:  Nat Rev Immunol       Date:  2017-10-16       Impact factor: 53.106

Review 5.  The impact of the gut microbiome on extra-intestinal autoimmune diseases.

Authors:  Eiji Miyauchi; Chikako Shimokawa; Alex Steimle; Mahesh S Desai; Hiroshi Ohno
Journal:  Nat Rev Immunol       Date:  2022-05-09       Impact factor: 53.106

6.  Antibiotic exposures and the development of pediatric autoimmune diseases: a register-based case-control study.

Authors:  Heli T Viljakainen; Kaija-Leena Kolho; Laura K Räisänen; Sohvi E Kääriäinen; Reijo Sund; Elina Engberg
Journal:  Pediatr Res       Date:  2022-07-19       Impact factor: 3.953

7.  Antibiotics, acetaminophen and infections during prenatal and early life in relation to type 1 diabetes.

Authors:  German Tapia; Ketil Størdal; Karl Mårild; Christian R Kahrs; Torild Skrivarhaug; Pål R Njølstad; Geir Joner; Lars C Stene
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196

8.  Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice.

Authors:  Rui Li; Hexing Wang; Qingfeng Shi; Na Wang; Zhijie Zhang; Chenglong Xiong; Jianxiang Liu; Yue Chen; Lufang Jiang; Qingwu Jiang
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

Review 9.  Gut microbiome in type 1 diabetes: A comprehensive review.

Authors:  Peilin Zheng; Zhixia Li; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2018-07-17       Impact factor: 4.876

10.  Short and long-term effects of a synbiotic on clinical signs, the fecal microbiome, and metabolomic profiles in healthy research cats receiving clindamycin: a randomized, controlled trial.

Authors:  Jacqueline C Whittemore; Jennifer E Stokes; Nicole L Laia; Joshua M Price; Jan S Suchodolski
Journal:  PeerJ       Date:  2018-07-17       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.